

Polycythemia Vera (PV)

Effective Date: October 2025



Background

Polycythemia vera (PV) is a clonal stem cell disorder characterized by erythrocytosis, with the majority of cases caused by constitutive activation of the *JAK-STAT* signal transduction pathway. The disease is associated with burdensome symptoms, reduced quality of life, thrombohemorrhagic complications and potential transformation to myelofibrosis (MF), myelodysplastic syndrome and/or acute myeloid leukemia (AML)^{1,2}.

Guideline Questions

1. What diagnostic and baseline investigations are recommended for adult patients with suspected or confirmed PV?
2. What are the recommended treatment options for PV?

Search Strategy

This guideline was generated using systematic literature searches of PubMed and MEDLINE databases, ASCO abstracts and proceedings, and ASH abstracts and proceedings. The search included practice guidelines, systematic reviews, meta-analyses, randomized controlled trials and clinical trials. The guidelines were also adapted from the Canadian MPN Group recommendations.

Target Population

The following guidelines apply to adults over the age of 18 years. Different principles may apply to pediatric patients.

Recommendations

1. Polycythemia vera (PV) should be considered when there is persistent elevation of hemoglobin (>165 g/L in men and >160 g/L in women) or hematocrit (>49% in men and >48% in women).
2. *JAK2V617F* mutation testing and erythropoietin levels should be performed when PV is suspected.
3. Bone marrow biopsy and aspiration may be necessary in some cases to confirm the diagnosis of PV and to distinguish PV from other myeloproliferative neoplasms.
4. PV is highly likely when *JAK2V617F* mutation is present and erythropoietin level is subnormal. When *JAK2V617F* mutation is seen with normal erythropoietin level, bone marrow biopsy is recommended to differentiate PV from other MPNs. When *JAK2V617F* is normal and erythropoietin is low, consider *JAK2* exon 12 mutational analysis or alternative diagnosis of congenital polycythemia. *JAK2* exon 12 testing may be performed via Next Generation Sequencing (NGS) which is performed by the molecular pathology laboratories in Edmonton

and Calgary. This test is ideally performed on a bone marrow biopsy, but it may be ordered on peripheral blood if the order is placed by a hematologist or hematopathologist.

5. Wildtype *JAK2V617F* and normal or high erythropoietin level makes PV very unlikely, and patients should be investigated for secondary causes of polycythemia.
6. Investigations for secondary polycythemia that may be indicated include:
 - i. Chest x-ray
 - ii. Pulse oximetry
 - iii. Arterial blood gas including carboxyhemoglobin and methemoglobin levels
 - iv. Kidney and liver function tests
 - v. Abdominal imaging studies (ultrasound or CT scan)
 - vi. Oxyhemoglobin dissociation curve
 - vii. Sleep studies
7. All patients should be treated with phlebotomy to target hematocrit less than 45%.
8. Low-dose acetylsalicylic acid (ASA) should be used in **all patients** without a contraindication.
9. In **high-risk** PV patients (age ≥ 60 years and/or history of thrombosis), cytoreductive therapy should be used with or without phlebotomy in combination with low dose ASA.
10. Conventional cardiovascular risk factors (diabetes, hypertension, hyperlipidemia) should be aggressively managed, and cigarette smoking should be discouraged.
11. Thromboembolic events should be managed according to accepted management guidelines.
12. Thromboprophylaxis should be used after surgery and in other high-risk situations.

Discussion

Pathogenesis

Polycythemia vera (PV) is a *BCR-ABL1*-negative myeloproliferative neoplasm (MPN) characterized by erythrocytosis (with increased red cell mass) that is often accompanied by leukocytosis and thrombocytosis. Constitutive *JAK-STAT* signaling caused by the *JAK2V617F* mutation within exon 14 is present in ~ 95% of PV patients and by different mutations within exon 12 of the *JAK2* gene (4% of PV patients), which are responsible for the pathogenesis of PV^{3,4}. The presence of *JAK2V617F* or a higher allele burden is not directly associated with PV survival or transformation rates^{5,6}, however, increased *JAK2V617F* allele burdens have been associated with fibrotic transformation⁷.

Clinical Manifestations

The estimated incidence of PV is ~ 2.8 per 100,000 among men and ~1.3 per 100,000 in woman with a prevalence of 22 cases per 100,000. [\[Link\]](#). The median age of presentation is in the 6th decade of life with only 1/3 of patients diagnosed younger than 50 years of age⁸.

The symptoms of PV can be variable with a majority of patients diagnosed incidentally by bloodwork. Splenomegaly is present in 30-40% of patients⁹. Non-specific symptoms such as headache, weakness, dizziness, and excessive sweating are present in 30% to 50% of PV patients and are often related to hyperviscosity resulting from erythrocytosis^{10,11}. Fatigue is common and may be related to iron deficiency often found in PV patients at diagnosis, even before the onset of therapeutic phlebotomy.

Specific symptoms such as pruritus, especially after warm baths or showers (aquagenic pruritus) is reported in 70% of patients and suspected to be related to the degranulation of increased mast cells in the skin of PV patients, releasing histamine and other inflammatory mediators^{12,13}. Erythromelalgia, described as burning pain in the feet and/or hands accompanied by erythema is seen in up to 28% of patients resulting from microvascular thrombosis and ischemia due to platelet activation and aggregation¹⁴. Both arterial and venous thrombotic events are a major cause of morbidity and mortality in PV. The incidence of thrombosis is approximately 18 x 1000 person years and accounts for 45% of all PV deaths⁹.

Diagnostic Evaluation

In the setting of isolated erythrocytosis, it is important to distinguish between primary and secondary polycythemia. Secondary polycythemia is caused by various factors driving erythropoiesis and may include hypoxia-driven mechanisms such as smoking, sleep apnea/hypoventilation, cardiac or pulmonary disease, high altitude or renal artery stenosis. Alternatively, oxygen-independent mechanisms include: drugs (androgens, erythropoietin, tumors- hepatic, renal, hemanigioblastomas) or post renal transplant². Relative polycythemia should also be ruled out and is characterized by an isolated decrease in plasma volume with resultant elevation of hemoglobin, hematocrit and red blood cell count without an increase in red cell mass. Gaisbock's disease, stress erythrocytosis or spurious polycythemia refer to states of chronically low plasma volumes. A careful history and physical exam with select investigations can help distinguish PV from secondary causes (**Table 1**). The following basic investigations are recommended: pulse oximetry and/or arterial oxygen saturation, complete blood count with differential, liver and renal studies, chest xray.

If erythrocytosis is accompanied by thrombocytosis and/or leukocytosis, PV should be strongly considered. Assessing an erythropoietin level (EPO) is a very reliable discriminatory test. More than 85% of patients with PV have low serum EPO concentrations. EPO levels above normal are unusual for PV and suggest secondary erythrocytosis, with a specificity of 98 %^{15,16}. It should be noted, to get

an accurate EPO level, testing should be performed before initiation of phlebotomies. Investigations for PV should begin with screening for serum erythropoietin levels and *JAK2V617F* mutation. A diagnostic algorithm is shown in **Figure 1**. Low serum EPO levels in the absence of *JAK2 V617F* requires additional mutational analysis for *JAK2* exon 12 mutations. If EPO levels are normal or elevated with no secondary causes found, consider high-affinity hemoglobinopathies with further investigations including oxyhemoglobin dissociation curves (P50). A low P50 suggests a high affinity hemoglobinopathy or familial 2,3-bisphosphoglycerate (2,3-BPG) deficiency in contrast normal P50 results may require VHL, PHD2/HIF α mutational testing^{2,17}.

Bone marrow (BM) evaluation in *JAK2 V617F*-positive patients with erythrocytosis has traditionally provided limited additional value for diagnostic purposes and is not routinely performed. However, a baseline BM biopsy might be required in cases where the diagnosis is unclear. Cytogenetic studies are not routinely performed in PV patients in Canada. Approximately 11% of PV patients have cytogenetic abnormalities which include: trisomy 8, trisomy 9, 13q-, and 20q-¹⁸, which are not specific to PV and found in other myeloid disorders. Cytogenetic abnormalities are more common in older PV patients (>60 years of age), and increase in frequency with disease progression and transformation¹⁹. The prognostic value of cytogenetics in PV remains unclear and still under investigation.

Figure 1: Diagnostic algorithm for polycythemia vera




Table 1: Differential Diagnosis of Polycythemia:

Normal Red Cell Mass:
Relative polycythemia Gaisbock's syndrome
Elevated Red Cell Mass:
<i>Primary Polycythemia (JAK2 V617F or exon 12 mutation)</i>
<i>Secondary Polycythemia</i>
<i>Appropriately elevated EPO level (hypoxia driven):</i>
Chronic pulmonary disease Right –to –left cardiac shunts Sleep apnea Massive obesity (Pickwickian syndrome) High altitude Chronic carbon monoxide poisoning/chronic smoking Red cell defects: methemoglobinemia Renal artery stenosis
<i>Inappropriately elevated EPO (non-hypoxia driven):</i>
Renal cell carcinoma Hepatocellular carcinoma Cerebellar Hemangioblastoma Uterine fibroids Pheochromocytoma
<i>Congenital/Familial Polycythemia:</i>
Activating mutations of erythropoietin receptor (EPOR gene) Chuvash polycythemia (VHL gene mutation) Other rare gene mutations (PHD2, HIF2-alpha)
<i>Miscellaneous:</i>
Drugs: Androgens/Anabolic steroids/Erythropoetin Renal transplant

Table 2: Evaluation of Secondary Causes of Polycythemia

Differential Diagnosis of Secondary Polycythemia	Investigations to Consider:
<i>Hypoxia Driven:</i> Cardiac or Pulmonary Disease	Pulse oximetry Arterial Blood Gas Chest X-ray Pulmonary Function tests Echocardiogram
Sleep Apnea High oxygen affinity hemoglobin	Overnight oximetry +/- Polysomnography Oxyhemoglobin dissociation curve
<i>Non-hypoxia driven:</i> Hepatic or Renal tumors Uterine Fibroids	Liver and Renal studies US abdomen/pelvis or CT abdomen/pelvis

Diagnosis

The diagnosis of PV is based on World Health Organization (WHO) criteria utilizing a composite assessment of clinical and laboratory features as shown in **Table 3**. Recently, 2016 revisions of the WHO classification have been made that have modified diagnostic hemoglobin levels as well as the utility of BM morphology. A bone marrow biopsy is not uniformly required in all cases, in particular, if patients meet previously defined WHO 2008 hemoglobin requirements and there is low likelihood of masked PV. **Figure 1** demonstrates an approach to diagnosis with indications for additional molecular testing and bone marrow biopsy. The rationale for the changes is based on recent observations that some *JAK2 V617F*-positive PV patients present with hemoglobin levels lower than the 2008 WHO threshold with characteristic bone marrow findings of PV. This would be classified as “masked PV” (mPV) and such patients may have increased risk of thrombosis, secondary to late diagnosis and resulting inadequate disease control²⁰⁻²². In PV, the classical BM features are increased cellularity with trilineage proliferation (panmyelosis). Megakaryocytes are pleomorphic with varying sizes without significant abnormalities in maturation and minimal reticulin fibrosis (grade1-2) is present²³.

Table 3: World Health Organization Diagnostic Criteria for Polycythemia Vera

	2008 WHO diagnostic criteria ^a	2016 WHO Diagnostic criteria ^b
Major Criteria	1) Hgb >185 g/L (men); >165 g/L (women) [†] 2) Presence of <i>JAK2V617F</i> or <i>JAK2</i> exon 12 mutation	1) Hgb >165 g/L (men); >160g/L (women) OR HCT>49% (men) and HCT >48% (women) OR increased red cell mass(RCM)* 2) BM hypercellular for age with trilineage myeloproliferation 3) Presence of <i>JAK2V617F</i> or <i>JAK2</i> exon 12 mutation
Minor Criteria	1) BM hypercellular for age and trilineage myeloproliferation 2) Subnormal serum EPO Level 3) Endogenous erythroid colony formation in vitro	1) Subnormal serum erythropoietin level

a PV diagnosis requires meeting BOTH major criteria and 1 minor criterion OR first major criterion and 2 minor criteria.

b PV diagnosis requires meeting ALL 3 major criteria, OR first 2 major criteria and the minor criteria

*More than 25% above mean predicted value.

[†] OR Hgb or Hct >99th %ile of ref range for age, sex or altitude OR increased red cell mass* OR Hgb >170 g/L (men) or >150 g/L (women) if associated with sustained increase of ≥ 20g/L from baseline not attributed to correction of iron deficiency

Prognosis

Patients with PV have a shortened life expectancy compared with the age and sex-matched general population, with an estimated 10-year survival being 28% lower in PV patients¹⁷. The median survival of PV patients is approximately 14 years; or 24 years if younger than age 60 at diagnosis²⁴. Based on

large cohort studies, risk factors for survival include: advanced age, leukocytosis, venous thrombosis and abnormal karyotype. A prognostic model was developed to predict survival with adverse points for ≥ 67 years (5 points), age 57–66 years (2 points), leukocyte count $\geq 15 \times 10^9/L$ (1 point) and venous thrombosis (1 point), resulting in low-risk (0 points), intermediate-risk (1 or 2 points) and high-risk (≥ 3 points) groups with median survivals of 27.8 years, 18.9 years and 10.9 years, respectively¹⁷. This was validated in a population-based PV study of 327 patients whereby age >70 , leukocyte count $>13 \times 10^9/L$ and thrombosis at time of diagnosis resulted in poorer survival with 10-year survival rates of 84%, 59% or 26% with the presence of none, one or ≥ 2 risk factors²⁵. Overall, 45% of PV-related deaths are associated with cardiovascular disease²⁶.

Approximately 10% of PV patients transform into post-polycythemia vera myelofibrosis (PPV-MF), with progressive splenomegaly, MF-related symptoms, and anemia²⁷. The IWG criteria for PPV-MF is shown in **Table 4**. Disease duration (>10 years) and *JAK2V617F* allele burden ($>50\%$) are associated with a higher risk of evolution to PPV-MF^{7,26}. The risk of leukemic transformation has been reported at 2.3% at 10 years and 5.5% at 15 years and remains $<10\%$ at 20 years. Older age, abnormal karyotype, and leukocytes $\geq 15 \times 10^9/L$ are independent risk factors for leukemic transformation^{17,28}. Post PV AML is an aggressive disease with very poor outcomes. Intensive chemotherapy followed by consolidated by allogeneic transplant is recommended in young fit patients. Hypomethylating agents and/or experimental therapies can be considered^{29,30}.

Table 4: International Working Group (IWG) definition of Post Polycythemia Myelofibrosis³¹.

Required Criteria:	
1.	Previous WHO diagnosis of PV
2.	BM fibrosis (grade 2 or 3 of 3-point scale)
Additional Criteria (2 required):	
1.	Anemia (Hgb < 135 g/L men, <120 g/L women)
2.	Leukoerythroblastic peripheral blood
3.	Increased splenomegaly
4.	≥ 1 constitutional symptoms ($\geq 10\%$ weight loss/6 months, drenching night sweats, unexplained fevers $> 37.5^\circ C$)

Table 5: Prognostic Models in PV


Prognostic Model:	Risk Categories:
Thrombosis score (European Leukemia NET)³⁵ Risk factors: Age ≥ 60 years Previous arterial or venous thrombosis	Low risk: 0 RFS High Risk: ≥ 1 RFs
IPSS Overall Survival³⁰ Risk factors: Age ≥ 67 yr (5 points) Age 55-66 yr (2 points) WBC $\geq 15 \times 10^9/L$ (1 point) Previous VENOUS thrombosis (1 point)	Low risk: 0 points (Median survival 28 years) Intermediate Risk: 1-2 points (Median survival 19 yrs) High risk: ≥ 3 points (Median survival 11 years)

Treatment

The main goal of therapy in PV is to prevent thrombohemorrhagic complications and control symptoms. The currently available treatments are non-curative. All patients should be counselled regarding their disease course and associated complications with management of their vascular risk factors. Currently, there are no specific lipid or blood pressure target ranges for individuals with PV. However, with the increased risk of arterial thrombosis, it is important that patients control atherosclerotic risk factors such as hypertension, dyslipidemia, diabetes and obesity as well as smoking cessation. The Framingham Heart Study and the risk assessment tools incorporated in current Canadian Cardiovascular Society guidelines should be applied for general prevention of cardiovascular disease³².

The European Leukemia Net (ELN) guidelines for Philadelphia-Negative Classical Myeloproliferative neoplasms (MPNs) recommends that **all patients** with PV be managed with phlebotomy to maintain a hematocrit (HCT) below 45%, and low-dose Aspirin³³. Current risk stratification in PV is based on an estimate of thrombosis risk (**Table 5**) and patients are treated according to their risk group (**Figure 2**). The ELN has also defined criteria for response which are mainly intended for standardization in clinical trials and are not typically applied as rigorously in clinical practice³⁴.

Figure 2: Treatment algorithm for PV



Low-risk patients:

Treatment options for low risk patients include phlebotomy and low-dose Aspirin (81 -100 mg/day)³³ (Figure 2).

Phlebotomy.

Phlebotomy is well tolerated and can be performed as an emergency therapy if patients are experiencing symptoms of hyperviscosity as well as an important treatment for long-term maintenance in PV^{34,35}. Typically, initial phlebotomy involves removal of 500 mL of blood every other day until a hematocrit of <45% is achieved. Lower quantity (i.e 250 mL) and frequency of phlebotomy should be considered in the elderly or patients with multiple comorbidities such as cardiovascular disease. Once an optimal hematocrit has been obtained a CBC can be assessed every 4-8 weeks and phlebotomy maintenance can be arranged accordingly (i.e every 2-3 months) to maintain Hct levels. Frequent phlebotomies will lead to iron deficiency and eventually result in reactive thrombocytosis and microcytosis. As a result, phlebotomy-induced iron deficiency can lead to complications such as increasing fatigue and restless leg syndrome. Iron supplementation is generally avoided in the setting of PV⁹.

Based on several studies, the recommended HCT target in PV is < 45%^{36,37}. The 2013 Italian Cyto-reductive Therapy in Polycythemia Vera (CYTO-PV) was a multicenter, randomized controlled trial (n=365) that compared maintaining a HCT of $\leq$ 45% “low hematocrit” to a HCT between 45-50% (“high hematocrit”) using phlebotomy and/or hydroxyurea. The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. At a median follow-up of 31 months, the primary end point was 2.7% among those with a HCT of <45% compared to 9.8% in the “high hematocrit” group (HR 3.91; 95% CI, 1.45 to 10.53; P = 0.007). There was no significant between-group difference in the rate of adverse events³⁷.

Low-dose Aspirin.

The randomized, placebo-controlled, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) study (n=518) demonstrated a significant risk reduction (RR 0.40) in a combined endpoint of cardiovascular events and venous thrombotic events (nonfatal MI, nonfatal stroke, PE, major venous thrombosis or death from CV causes) with the use of low-dose Aspirin (100 mg daily) over placebo, with no significant increased risk of bleeding³⁶. Based on this data, daily low-dose Aspirin is recommended for all PV patients in the absence of contraindications³³. Low dose Aspirin is effective in alleviating vasomotor microvascular symptoms particularly erythromelalgia, which are resulting from platelet-rich arteriolar microthrombi³⁸.

High-risk patients:

High risk patients as shown in **Table 5** (≥ 60 years of age and/or prior history of thrombosis) should be on cytoreductive therapy³³. Cytoreductive therapy can be considered on an individual case basis (irrespective of risk) in patients with any of the following features⁹: (Figure 2)

- i. Extreme thrombocytosis (platelet count $\geq 1500 \times 10^9/L$) or if thrombocytosis is associated to bleeding or avWD
- ii. Progressive leukocytosis $\geq 20 - 25 \times 10^9/L$
- iii. Symptomatic splenomegaly
- iv. Severe disease-related symptoms
- v. Intolerance to phlebotomy

Cytoreductive therapies.

The European Leukemia Net (ELN) guidelines recommend either hydroxyurea or interferon- α as first-line cytoreductive therapy³³.

Hydroxyurea.

Hydroxyurea (HU) is an oral antimetabolite that prevents DNA synthesis by inhibiting the enzyme ribonucleoside reductase. Hydroxyurea is typically started at a dose of 15-20mg/kg/day (~1000mg/day). After a response is attained, a maintenance dose is continued to ensure a CBC remains within a normal range with CBC initially performed monthly and every 3 months thereafter once in a steady state⁹. Hydroxyurea is well tolerated with side effects including skin and nail changes, gastrointestinal toxicities, oral and leg ulcers myelosuppression and development of macrocytosis⁹.

In the Polycythemia Vera Study Group (PVSG) trial, patients treated with HU had a lower incidence of thrombosis compared with historical controls treated with phlebotomy (9.8% vs. 32.8%)³⁹. Long-term outcomes comparing hydroxyurea to pipobroman were reported in the French Polycythemia Study Group (FPSG) study, which randomly assigned HU versus pipobroman as first-line therapy in 285 patients < 65 years old. Median survivals were 20.3 and 15.4 years for the HU and pipobroman, respectively ($P = .008$). At 10, 15, and 20 years, cumulative incidence of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was 6.6%, 16.5%, and 24% in the HU arm and 13%, 34%, and 52% in the pipobroman arm ($P = .004$). Cumulative myelofibrosis incidence at 10, 15, and 20 years was 15%, 24%, and 32% with HU versus 5%, 10%, and 21% with pipobroman ($P = .02$). This illustrated the higher leukemogenic potential for pipobroman and its lack of suitability as first-line therapy in PV⁴⁰. Hydroxyurea became a preferred first-line agent and although the incidence of evolution to AML with HU has been reported, it has been considered significantly lower than historical controls treated with chlorambucil or radiophosphorus (5.9% vs. 10.6% vs 8.3%, respectively)³⁹. Studies have confirmed a low incidence of AML in PV patients treated with hydroxyurea and that exposure to P32, busulphan, and pipobroman (HR, 5.46; 95% CI, 1.84-16.25; $P = .0023$), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; $P = .8021$), increases the risk for progression

to AML/MDS compared with treatment with phlebotomy or interferon³¹. The data for HU use in PV is also extrapolated from essential thrombocythemia (ET) studies. Cortelazzo et al. randomized 114 high-risk ET patients to HU versus no therapy. At a median follow-up of 27 months, 3.6% of patients on HU experienced a thrombotic event compared to 24% of those in the control group⁴¹. Likewise, in 809 high-risk ET patients, HU plus low dose Aspirin (100mg/day) was compared to Anagrelide plus low dose Aspirin. Hydroxyurea resulted in better reduction of arterial thrombosis, major bleeding and fibrotic progression. Anagrelide resulted in lower venous thrombosis rates however patients on this treatment were more likely to withdraw from their assigned treatment (P<0.001)⁴². The ANAHYDRET study, was a prospective randomized noninferiority phase 3 study of 259 high-risk ET patients. During the total observation time of 730 patient-years, there was no significant difference between the anagrelide and hydroxyurea group regarding incidences of arterial and venous thrombosis, bleeding events, or rates of discontinuation. Disease transformation into myelofibrosis or secondary leukemia was not reported in this study. Anagrelide was considered not inferior compared with hydroxyurea in the prevention of thrombotic complications in patients with ET however, is not considered a first line treatment option in PV⁴³.

Although not a common problem in PV, the development of HU resistance or intolerance occurs and has been estimated as 11.5% in a median of 5.8 years from time of diagnosis. Hydroxyurea intolerance/resistance is associated with a 5.6 fold increase risk of death⁴⁴. The ELN panel of experts has developed a standardized definition of resistance and intolerance to HU in PV³¹ (**Table 6**). Younger patients with intolerance/resistance are alternatively treated with Interferon- α therapy (IFN) or Ruxolitinib. Older patients can be treated with alternatives such as Ruxolitinib or select elderly patients may be considered for busulphan³³.

Table 6: Definition of Hydroxyurea Intolerance/Resistance In PV³¹.

Any of the following criteria:
1. Need for phlebotomy to keep HCT <45% after 3 months of at least 2 g/day of HU
2. Uncontrolled myeloproliferation: plt >400 x 10 ⁹ /L AND WBC >10 x 10 ⁹ /L after 3 months of at least 2 g/day of HU
3. Failure to reduce massive splenomegaly* by more than 50% as measured clinically, OR failure to completely relieve symptoms related to splenomegaly, after 3 months of at least 2 g/day of HU
4. Persistent cytopenias: ANC <1 x 10 ⁹ /L OR plt <100 x 10 ⁹ /L OR Hgb <100 g/l at the lowest dose of HU required to achieve a complete or partial response§
5. Presence of leg ulcers or other unacceptable HU-related toxicities, such as mucocutaneous manifestations, GI symptoms, pneumonitis or fever

*Spleen more than 10 cm from the costal margin.
 §Complete response defined as: Hct <45% without phlebotomy, platelet count ≤400 x 10⁹/L, WBC ≤ 10 x 10⁹/Land no disease related symptoms. Partial response defined as: Hct <45% without phlebotomy, or response in three or more of the other criteria³⁷.

Interferon.

Both short-acting Interferon (IFN) and pegylated interferon (IFN)- α are effective in controlling blood counts as well as spleen size and symptoms (aquagenic pruritus) in PV, and is considered first-line

therapy, particularly in younger patients (< 40 years)^{33,45}. Unfortunately, side effects can limit therapy and include autoimmune disorders, flu-like manifestations, depression, heart and ocular disease which have led to permanent discontinuation in 20% to 40% of patients on conventional IFN and 20% to 25% on pegylated IFN⁴⁵. It is contraindicated in patients with mental disorders. IFN is commonly administered subcutaneously at a starting dose of 3 million units daily until a response is achieved. Pegylated interferons such as PEG-IFN- α 2a (Pegasys), is given at a starting dose of 45 to 90 μ g weekly, titrated up to a dose of 180 μ g weekly. The dose should be titrated individually based on efficacy and toxicity with CBC. Apart from the absence of leukemogenic risk, the other benefit of IFN may be its ability to attain molecular responses^{45,46}. A phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with ET (n=39) and PV (n=40) demonstrated that PEG-IFN-alpha-2a reduces the size of the malignant clones measured by JAK2 allele burden. Overall hematologic response rate was 80% in PV and 81% in ET (complete in 70% and 76% of patients, respectively). Molecular response rates were 38% in ET and 54% in PV, with complete (undetectable JAK2(V617F)) in 6% and 14%, respectively⁴⁶.

Myeloproliferative Disorders Research Consortium 112 (MPD-RC 112 (NCT01259856)), was an investigator-initiated, phase 3 trial comparing HU to pegylated IFN-a (PEG) in treatment-naïve, high-risk patients with either ET or PV, with primary endpoint of complete response (CR) at 12 months. Among 168 patients, treated for a median of 81.0 weeks, CR at 12 months, was similar for HU at 37% and 35% for PEG (P= 0.80). ORR at 12 months was 70% for HU and 78% for PEG (P=0.22). Forty-three percent and 65% of patients with PV receiving HU and PEG, respectively, achieved hematocrit control (without phlebotomy) at 12 months (P =0.04). Platelet control in ET patients at 12 months was 45% and 46% for patients receiving HU and PEG, respectively (P = .93). At 24 to 36 months, CR was 20% to 17% for HU and 29% to 33% for PEG with an ORR of 41% for HU and 60% for PEG (P = .045). In 57 patients (HU: 30; PEG: 27), the CR at 36 months was 17% for HU and 33% for PEG, and ORR was 47% for HU and 59% for PEG (P = .34 for ORR comparison). A greater reduction in JAK2V617F allelic burden at 24 months was achieved with PEG, however this did not correlate with histopathology whereby, histopathologic responses were more frequent with HU. Thrombotic events and disease progression were infrequent in both arms and not different, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)⁴⁷. Newer formulations of PEG-IFN include ropeginterferon alfa-2b (Besremi; Ropeg [Europe]), which has been studied most recently in comparison with HU for various MPNs and is a monopegylated, long-acting interferon administered once every 2 weeks or longer. It was FDA approved for PV at the end of 2021 based on results from the phase 3 PROUD/CONTINUATION-PV clinical trials. In the CONTINUATION-PV trial, which included 171 patients, 61% of patients on ropeginterferon alfa-2b met complete hematologic response (CHR), defined as hematocrit < 45% without phlebotomy for at least 2 months after last phlebotomy, platelets $\leq 400 \times 10^9/L$, leukocytes $\leq 10 \times 10^9/L$, normal spleen size with improved disease burden markers⁴⁸. Over 6 years of follow-up, ropeginterferon improved event-free survival vs hydroxyurea/best available therapy (BAT): EFS probability 0.94 vs 0.82; HR 0.34 (95% CI 0.12–0.97), p=0.04. It also achieved higher complete hematologic response (CHR) rates at 72 months (54.5% vs

34.9%; sensitivity analysis 72.6% vs 47.3%). Molecular responses were markedly higher: 66% achieved ELN molecular response and median JAK2 V617F allele burden fell to 8.5% at 72 months (vs 50.4% with control). Safety was largely grade 1–2 with comparable grade ≥ 3 rates to control over the period⁴⁹.

National Comprehensive Cancer (NCCN) MPN guidelines were updated in 2023. These guidelines suggested that ropeginterferon alfa-2b (Besremi) be the preferred treatment option for patients with high-risk PV with alternative first-line option being hydroxyurea. These guidelines also suggested Besremi be the preferred first-line method for cytoreduction in adults with low-risk, symptomatic PV [NCCN [Link](#)].

Trials on optimal dosing strategies and titration of Besremi are in progress such as ECLIPSE-PV (NCT04182100), which is a randomized, open-label, multicenter trial in patients with PV in the USA and Canada. This is comparing an approved starting dosing schema titration with 50 mcg subcutaneous every 2 weeks and takes approximately 20 weeks to reach a plateau of maximal dosing of 500 mcg. In contrast to higher and faster titrations starting from 250 mcg SC to 350 mcg and subsequently 500 mcg SC over a 6-week transition. Current dosing recommendations are outlined below. ECLIPSE-PV will evaluate the primary endpoint of complete hematologic response (CHR) rate at week 24. CHR is defined as hematocrit $<45\%$, white blood cells $<10 \times 10^9/L$, platelets $\leq 400 \times 10^9/L$ without phlebotomy in the previous 12 weeks. Secondary endpoints include molecular response, safety, tolerability, and quality of life⁵⁰.

Besremi is not formally Health Canada approved however, with the current 2024 shortages of Pegasys, a Health Canada Exceptional access to Besremi for MPN treatment has been established [[Link](#)].

Below are current treatment recommendations for dosing between IFN based treatments as well as starting dose in patients beginning Besremi de novo versus on Hydroxyurea cytoreduction [[Link](#)].

Starting & titration (q2 weeks, subcutaneous):

- **Not on hydroxyurea (HU):** Start **100 mcg** every **2 weeks**. Increase by **50 mcg** every **2 weeks** to a **max 500 mcg**, until hematologic parameters are stabilized (Hct $<45\%$ without phlebotomy, Plt $<400 \times 10^9/L$, WBC $<10 \times 10^9/L$).
- **Transitioning from HU:** Start **50 mcg** every **2 weeks** with HU. Taper HU by reducing the **total biweekly HU dose 20–40% every 2 weeks** during **Weeks 3–12**, while **increasing BESREMi by 50 mcg every 2 weeks** to a **max 500 mcg**; **discontinue HU by Week 13** when counts are stable.

Maintenance interval:

- Once stable counts are maintained for **≥ 1 year on a stable dose**, you **may extend** the dosing interval to **every 4 weeks** at the same dose.

Monitoring:

- **CBC every 2 weeks** during titration; then **every 3–6 months** during maintenance (more often if needed). Phlebotomy may be used as rescue during titration.

Dose modifications (selected label triggers):

- **Cytopenias (e.g., Hgb <80 g/L, Plt <50000/μL, WBC <2.0):** reduce by **50 mcg**; continue step-downs q2 weeks until recovery (Hgb >10, Plt >75k, WBC >3.0k/μL). Resume cautious re-escalation after recovery if needed.
- **Liver enzyme elevations:** stepwise **dose reductions or interruption** per label thresholds; consider discontinuation if persistent despite up to four dose modifications.

Transitioning established patients on Pegasys:

There is not an exact conversion between IFN formulations— BESREMi ≈ 70% of Pegasys dose. Dosing should be individualized based on response and tolerance. After achieving stable control, spacing to monthly or longer intervals is permissible to reduce injection burden and support supply efficiency [\[Link\]](#).

Current subcutaneous Pegasys Dose	Suggested subcutaneous BESREMi Dose
45 μg weekly	Ramp Pegasys to 90 μg q2w or 65–125 μg BESREMi
90 μg weekly	125 μg q2weeks
135 μg weekly	200 μg q 2weeks
180 μg weekly	250 μg q 2weeks

For patients on **Pegasys every 2 weeks**, approximate monthly BESREMi doses:

Pegasys Dose	BESREMi qMonthly Dose
45 μg q2weeks	Pegasys → 90 μg every 4 weeks or 125 μg BESREMi monthly
90 μg q2weeks	125 μg q4weeks
135 μg q2weeks	200 μg q 4weeks
180 μg q2weeks	250 μg q 4weeks

Second line therapies:

Ruxolitinib.

Ruxolitinib is a JAK1/JAK2 inhibitor that has demonstrated clinical benefit and has been approved in patients with myelofibrosis^{51,52}. A phase II study of PV patients (n=34) who were intolerant or refractory to HU received ruxolitinib for a median of 35 months. Achievement of a HCT <45% without phlebotomy occurred in 97% of patients by week 24. Patients with palpable splenomegaly at baseline, resulted in 44% and 63%, respectively, having a nonpalpable spleen at weeks 24 and 144. The RESPONSE study was a phase III open-label study evaluating the efficacy and safety of ruxolitinib versus investigator determined best available therapy (BAT) in patients with polycythemia vera who were intolerant or refractory to HU. The primary end point was both hematocrit control and ≥ 35% reduction in spleen volume at week 32, based on imaging. The primary end point was achieved in 21% of the patients in the ruxolitinib group versus 1% of those in the BAT group (OR 28.64; 95% CI 4.50-1206; P <0.0001). Hematocrit control was achieved in 60% of patients receiving ruxolitinib and 20% of those receiving BAT. Spleen volume reduction occurred in 38% and 1% of ruxolitinib versus BAT patients, respectively. Ruxolitinib achieved ≥ 50% reduction in the total symptom score at week 32 in 49% versus 5% of those with BAT. Thromboembolic events occurred in one patient receiving ruxolitinib and in six patients receiving standard therapy however, further investigations are needed to determine its role in reducing thrombotic risk among PV patients²³. The most common hematologic adverse events (AEs) were anemia and thrombocytopenia; however, no patient in the RESPONSE trial discontinued treatment due to these cytopenias. Common non-hematologic AEs are headache, dizziness, diarrhea, and fatigue and there were herpes zoster infections noted in ~6% of patients. Ruxolitinib is now approved by Health Canada for treatment of PV patients resistant to or intolerant of a cytoreductive agent.

Symptom assessment

PV-related symptoms are troublesome to patients, and alleviation of this burden is an important treatment objective. It is important to carefully assess patients' symptoms and to have an objective means to monitor disease progression or response to treatment. The [Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score \(MPN-SAF TSS\)](#) is a validated objective tool for evaluating patient symptoms¹¹. The MPN-SAF TSS, also known as MPN10, is a shorter questionnaire that includes 10 items: fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fever. This score has been validated in a prospective study of 1433 patients and results correlated with other measures of disease burden and remains consistent between serial administrations¹¹.

Special Topics

Pregnancy

Typically, only 10% of PV patients are diagnosed at <40 years of age⁵³. PV increases risks for both fetus and mother with less than 60% of pregnancies occurring in PV patients being successful. Patients are at risk of miscarriages with first trimester losses being most common. Maternal complications include preeclampsia, postpartum hemorrhage and thrombosis^{45,53}. Phlebotomy should be used to keep the hematocrit at less than 45% but of note, the physiological changes of pregnancy often can reduce hematocrit levels. Female patients should be advised that HU is contraindicated in pregnancy and, therefore, appropriate contraceptive precautions should be taken while on this therapy and HU should be discontinued in setting of pregnancy. Interferon alfa-2b is recommended for those requiring cytoreductive therapy during pregnancy since all other cytoreductive agents are contraindicated due to possible teratogenic effects. Indications for cytoreduction in pregnancy include if platelet count >1500 x 10⁹/L or related complications of bleeding. There is some evidence that the use of low-dose aspirin throughout pregnancy improves live birth rate. The ELN has published treatment recommendations for PV patients during pregnancy (**Table 7**). It is recommended that prophylactic low-molecular-weight heparin (LMWH) be used for 6 weeks postpartum in all patients with consideration for its use during pregnancy in high risk pregnancy^{9,33}.

Table 7: Suggested management of PV patients during pregnancy based on ELN guidelines³³.

Pregnancy Risk	Management
LOW Risk	Target HCT < 45% Low dose ASA + Prophylactic dose LMWH postpartum x 6 weeks
HIGH Risk: Includes patients with prior thrombosis history, major bleeding due to MPN or severe pregnancy complication*	Target HCT <45% Low dose ASA + LMWH throughout pregnancy and postpartum

*Recurrent (≥3) first-trimester pregnancy loss, intrauterine growth restriction (IUGR), unexplained intrauterine death or if secondary to placental dysfunction, severe preeclampsia necessitating preterm delivery before 34 weeks, significant ante-postpartum hemorrhage, placental abruption, or marked sustained increase of platelets >1500 x 10⁹/L (Adapted from: Gerds A. *Oncology* 2017;92:179-189⁵⁴).

Perioperative Management:

Surgery in patients with PV has a high risk of both peri-operative bleeding and postoperative thromboembolism. In a multicenter retrospective study of 255 PV and ET patients, a high proportion of patients experienced vascular occlusions (7.7%) and major hemorrhage (7.3%)⁵⁵. Elective surgeries should be delayed until cytoreductive measures and/or phlebotomy can be used to achieve blood count control since risks may be lower with hematologic control prior to surgery⁵⁶. It is recommended that hematocrit maintenance <45% and normalization of blood counts be achieved ≥ 3 months prior to surgery⁵⁷. Aspirin should be held for 5-7 days before surgery to reduce the risk of hemorrhage. LMWH should be given after surgery to prevent deep venous thrombosis⁵⁷. Mechanical compression stockings are an option for patients with bleeding that prevents the use of anticoagulation. Ruxolitinib has potential rebound effects with discontinuation therefore it is recommended it be continued through surgery. If discontinuations are needed, a taper is required whereby it is discontinued 1-2 weeks prior to surgery⁵⁴. When thromboembolic events do occur, treatment should be according to current management guidelines. Indefinite anticoagulation should be considered because of the high risk of recurrent events.

References

1. Dameshek W. Some speculations on the myeloproliferative syndromes. *Blood*. 1951;6(4):372-375.
2. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. *American Journal of Hematology*. 2015;90(2):162-173. doi:10.1002/ajh.23895
3. James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434(7037):1144-1148. doi:10.1038/nature03546
4. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. *The New England Journal of Medicine*. 2007;356(5):459-468. doi:10.1056/NEJMoa065202
5. Tefferi A. Mutant molecules of interest in myeloproliferative neoplasms: introduction. *Acta Haematologica*. 2008;119(4):192-193. doi:10.1159/000140629
6. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. *Leukemia*. 2008;22(9):1790-1792. doi:10.1038/leu.2008.56
7. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. *Leukemia*. 2010;24(9):1574-1579. doi:10.1038/leu.2010.148
8. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. *Haematologica*. 2003;88(1):13-18.
9. Passamonti F. How I treat polycythemia vera. *Blood*. 2012;120(2):275-284. doi:10.1182/blood-2012-02-366054
10. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. *Cancer*. 2007;109(1):68-76. doi:10.1002/cncr.22365
11. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood*. 2011;118(2):401-408. doi:10.1182/blood-2011-01-328955
12. Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. *American Journal of Hematology*. 2013;88(8):665-669. doi:10.1002/ajh.23474
13. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. *European Journal of Clinical Investigation*. 2010;40(9):828-834. doi:10.1111/j.1365-2362.2010.02334.x
14. van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. *Seminars in Thrombosis and Hemostasis*. 1997;23(4):357-363. doi:10.1055/s-2007-996109
15. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. *Haematologica*. 2004;89(10):1194-1198.
16. Messinezy M, Westwood NB, El-Hemaidi I, Marsden JT, Sherwood RS, Pearson TC. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. *British Journal of Haematology*. 2002;117(1):47-53.
17. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia*. 2013;27(9):1874-1881. doi:10.1038/leu.2013.163
18. Gangat N, Strand J, Lasho TL, et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. *European Journal of Haematology*. 2008;80(3):197-200. doi:10.1111/j.1600-0609.2007.01003.x
19. Andrieux JL, Demory JL. Karyotype and molecular cytogenetic studies in polycythemia vera. *Current Hematology Reports*. 2005;4(3):224-229.
20. Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. *American Journal of Hematology*. 2014;89(6):588-590. doi:10.1002/ajh.23694
21. Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. *American Journal of Hematology*. 2014;89(2):199-202. doi:10.1002/ajh.23617
22. Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. *British Journal of Haematology*. 2014;167(4):541-546. doi:10.1111/bjh.13080
23. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *The New England Journal of Medicine*. 2015;372(5):426-435. doi:10.1056/NEJMoa1409002

24. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*. 2014;124(16):2507-2513; quiz 2615. doi:10.1182/blood-2014-05-579136
25. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythemia vera: a population-based study of 327 patients. *British Journal of Haematology*. 2013;160(2):251-254. doi:10.1111/bjh.12117
26. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2005;23(10):2224-2232. doi:10.1200/JCO.2005.07.062
27. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. *Blood*. 2008;111(7):3383-3387. doi:10.1182/blood-2007-11-121434
28. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood*. 2005;105(7):2664-2670. doi:10.1182/blood-2004-09-3426
29. Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. *Blood*. 2013;121(14):2725-2733. doi:10.1182/blood-2012-10-464248
30. Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. *Cancer*. 2005;104(5):1032-1036. doi:10.1002/cncr.21297
31. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. *British Journal of Haematology*. 2010;148(6):961-963. doi:10.1111/j.1365-2141.2009.08019.x
32. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol*. Nov 2016;32(11):1263-1282. doi:10.1016/j.cjca.2016.07.510
33. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2011;29(6):761-770. doi:10.1200/JCO.2010.31.8436
34. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. *Blood*. 2009;113(20):4829-4833. doi:10.1182/blood-2008-09-176818
35. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*. 2018;32(5):1057-1069. doi:10.1038/s41375-018-0077-1 [doi]
36. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *The New England Journal of Medicine*. 2004;350(2):114-124. doi:10.1056/NEJMoa035572
37. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *The New England Journal of Medicine*. 2013;368(1):22-33. doi:10.1056/NEJMoa1208500
38. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. *Platelets*. 2006;17(8):528-544. doi:10.1080/09537100600758677
39. Fruchtmann SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. *Seminars in Hematology*. 1997;34(1):17-23.
40. Kiladjan J-J, Chevret S, Dosquet C, Chomienne C, Rain J-D. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2011;29(29):3907-3913. doi:10.1200/JCO.2011.36.0792
41. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *The New England Journal of Medicine*. 1995;332(17):1132-1136. doi:10.1056/NEJM199504273321704
42. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *The New England Journal of Medicine*. 2005;353(1):33-45. doi:10.1056/NEJMoa043800
43. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. *Blood*. 2013;121(10):1720-1728. doi:10.1182/blood-2012-07-443770

44. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. *Blood*. 2012;119(6):1363-1369. doi:10.1182/blood-2011-10-387787
45. Kiladjian J-J, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood*. 2008;112(8):3065-3072. doi:10.1182/blood-2008-03-143537
46. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2009;27(32):5418-5424. doi:10.1200/JCO.2009.23.6075
47. Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. *Blood*. May 12 2022;139(19):2931-2941. doi:10.1182/blood.2021012743
48. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. *Lancet Haematol*. Mar 2020;7(3):e196-e208. doi:10.1016/s2352-3026(19)30236-4
49. Gisslinger H, Klade C, Georgiev P, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. *Leukemia*. 2023;2129-2132. vol. 10.
50. Mascarenhas J, Bose P, Hillis C, et al. ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. *Acta Haematol*. Mar 5 2025;1-7. doi:10.1159/000544818
51. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *The New England Journal of Medicine*. 2012;366(9):799-807. doi:10.1056/NEJMoa1110557
52. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *The New England Journal of Medicine*. 2012;366(9):787-798. doi:10.1056/NEJMoa1110556
53. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*. 2013;88(6):507-516. doi:10.1002/ajh.23417
54. Gerds AT, Dao K-H. Polycythemia Vera Management and Challenges in the Community Health Setting. *Oncology*. 2017;92(4):179-189. doi:10.1159/000454953
55. Ruggeri M, Rodeghiero F, Tosi A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. *Blood*. 2008;111(2):666-671. doi:10.1182/blood-2007-07-102665
56. Wasserman LR, Gilbert HS. SURGERY IN POLYCYTHEMIA VERA. *The New England Journal of Medicine*. 1963;269:1226-1230. doi:10.1056/NEJM196312052692302
57. Finazzi G, Barbui T. How I treat patients with polycythemia vera. *Blood*. 2007;109(12):5104-5111. doi:10.1182/blood-2006-12-038968

Development and Revision History

This guideline was developed by a multidisciplinary working group comprised of members from the Alberta Provincial Hematology Tumour Team, external participants identified by the Working Group Lead, and a methodologist from the Guideline Resource Unit. The draft guideline was externally reviewed and endorsed by members of the Alberta Provincial Hematology Tumour Team who were not involved in the guideline's development, including surgical oncologists, radiation oncologists, medical oncologists, hematologists, nurses, pathologists, and pharmacists. A detailed description of the methodology followed during the guideline development process can be found in the [Guideline Resource Unit Handbook](#).

This guideline was originally developed in 2020.

Maintenance

A formal review of the guideline will be conducted in 2026. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

2,3-BPG, 2,3-bisphosphoglycerate; AEs, adverse events; AML, acute myeloid leukemia; ASA, acetylsalicylic acid; BAT, best available therapy; BM, bone marrow; CBCD, complete blood count with differential; ELN, European Leukemia Net; EPO, erythropoietin; ET, essential thrombocythemia HCT, hematocrit; Hgb, hemoglobin; HU, hydroxyurea; IFN, interferon; IWG, international working group; LDS, lactate dehydrogenase; LMWH, low-molecular-weight-heparin; P50, oxyhemoglobin dissociation curve; PPV-MF, post-polycythemia vera myelofibrosis; PV, Polycythemia vera; MDS, myelodysplastic syndrome; MF, myelofibrosis; MPN, myeloproliferative neoplasm; mPV, masked PV; NGS, Next Generation Sequencing; RCM, red cell mass; WHO, whole health organization.

Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2025) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](#). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of Cancer Care Alberta's evidence-based clinical practice guidelines and supporting materials comes from the Cancer Care Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).

Conflict of Interest Statements

Dr. Sonia Cerquozzi (lead) reports personal fees, non-financial support and other from Novartis, personal fees, non-financial support and other from Celgene, personal fees from Pfizer, outside the submitted work.

Derek Tilley declares no conflicts of interest.

Citation

Cerquozzi S (lead), Tilley D. Cancer Care Alberta, Alberta Health Services (2025). Clinical Practice Guideline on [Polycythemia Vera, Version 2]. Accessed [Month, Year]. Available from: www.ahs.ca/guru